| 0 (0%) | 12-05 10:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.1 |
1-year : | 71.37 |
| Resists | First : | 52.31 |
Second : | 61.1 |
| Pivot price | 39.49 |
|||
| Supports | First : | 21.37 |
Second : | 2.24 |
| MAs | MA(5) : | 38.59 |
MA(20) : | 38.2 |
| MA(100) : | 39.99 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 43.5 |
D(3) : | 52.5 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 53.88 | Low : | 2.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABIO ] has closed above bottom band by 11.2%. Bollinger Bands are 149.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.83 - 29.07 | 29.07 - 29.22 |
| Low: | 2.21 - 2.23 | 2.23 - 2.24 |
| Close: | 28.46 - 28.86 | 28.86 - 29.14 |
Mon, 03 Nov 2025
ABio Materials, through its brand celexo, specializes - openPR.com
Sat, 09 Aug 2025
Ameriprise Financial Adds Veteran Advisor Vince Abio with $120M in Client Assets - Insider Monkey
Thu, 29 Aug 2024
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split - GlobeNewswire
Wed, 03 Apr 2024
Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 101.4 (%) |
| Shares Short | 4,990 (K) |
| Shares Short P.Month | 4,230 (K) |
| EPS | -5.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -20.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -4.9 |
| PEG Ratio | 0 |
| Price to Book value | 12.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.06 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 67.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|